Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Other: alpelisib plus fulvestrant
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05022342
- Locations
- 🇮🇳
Novartis Investigative Site, Kolkata, India
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
Terminated
- Conditions
- Sickle Cell Disease
- Interventions
- Other: Crizanlizumab
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT05020873
- Locations
- 🇸🇦
Novartis Investigative Site, Jazan, Saudi Arabia
Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT04993157
- Locations
- 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States
A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)
Phase 2
Terminated
- Conditions
- Mixed Connective Tissue DiseaseSjogren Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT04988087
- Locations
- 🇨🇳
Novartis Investigative Site, Kaohsiung, Taiwan
Regulatory Post-Marketing Surveillance Study for Brolucizumab
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Other: brolucizumab
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3000
- Registration Number
- NCT04985487
- Locations
- 🇰🇷
Novartis Investigative Site, Taegu, Korea, Republic of
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 211
- Registration Number
- NCT04984876
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸Allergy and Immunology Associates, Scottsdale, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
Phase 2
Active, not recruiting
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT04980833
- Locations
- 🇺🇸
Boston Childrens Hospital ., Boston, Massachusetts, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Phase 3
Active, not recruiting
- Conditions
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 406
- Registration Number
- NCT04971226
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists Pan, Tallahassee, Florida, United States
A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting
Terminated
- Conditions
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Interventions
- Other: AlpelisibOther: Fulvestrant
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04967248
- Locations
- 🇮🇹
Novartis Investigative Site, Potenza, Italy
Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT04961619
- Locations
- 🇹🇷
Novartis Investigative Site, Kecioren Ankara, Turkey
© Copyright 2025. All Rights Reserved by MedPath